Aligos Therapeutics (ALGS) Short-term Investments (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Short-term Investments came in at $24.9 million in Q1 2026, up 22562.73% YoY from N/an in Q1 2025, and up 22562.73% on a QoQ basis from $110000.0 in Q4 2025.
Aligos Therapeutics (ALGS) Short-term Investments (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Short-term Investments data on file, last reported at $24.9 million in Q1 2026.
- Quarterly Short-term Investments rose 22562.73% year-over-year to $24.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.9 million (up 22562.73% YoY) and the FY2025 annual result came in at $110000.0, down 99.45% from the prior year.
- Short-term Investments climbed to $24.9 million in Q1 2026, from $110000.0 in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $104.3 million in Q2 2025 to a low of $21000.0 in Q2 2022.
- A 5-year average of $18.4 million and a median of $110000.0 in 2025 frame the typical range for Short-term Investments.
- Annual changes were most pronounced in 2023 — Short-term Investments plunged 99.78% — and 2025, when it surged 148877.14%.
- Tracing ALGS's Short-term Investments over 5 years: stood at $44.5 million in 2022, then sank by 99.78% to $100000.0 in 2023, then surged by 19842.0% to $19.9 million in 2024, then plunged by 99.45% to $110000.0 in 2025, then jumped by 22562.73% to $24.9 million in 2026.
- The last three Short-term Investments figures came in at $24.9 million (Q1 2026), $110000.0 (Q4 2025), and $110000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aligos Therapeutics | 68.90 Mn | 38.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42,000.00 |
| Mar 31, 2026 | 24.93 Mn |
| Dec 31, 2025 | 110,000.00 |
| Sep 30, 2025 | 110,000.00 |
| Jun 30, 2025 | 104.28 Mn |
| Mar 31, 2025 | 110,000.00 |
| Dec 31, 2024 | 19.94 Mn |
| Sep 30, 2024 | 39.59 Mn |
| Jun 30, 2024 | 70,000.00 |
| Mar 31, 2024 | 216,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 74,000.00 |
| Jun 30, 2023 | 42,000.00 |
| Mar 31, 2023 | 397,000.00 |
| Dec 31, 2022 | 44.48 Mn |
| Sep 30, 2022 | 80,000.00 |
| Jun 30, 2022 | 21,000.00 |
| Mar 31, 2022 | 78.66 Mn |
| Dec 31, 2021 | 200,000.00 |
| Sep 30, 2021 | 653,000.00 |